➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: July 27, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for CYR-101

Email this page to a colleague

« Back to Dashboard

What is the drug development status for CYR-101?

CYR-101 is an investigational drug.

There have been 4 clinical trials for CYR-101. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2007.

The most common disease conditions in clinical trials are Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, and Leukemia. The leading clinical trial sponsors are Cyrenaic Pharmaceuticals, Pusan National University Hospital, and Novartis Pharmaceuticals.

Recent Clinical Trials for CYR-101
Vasodilators and Anti-Oxidant Therapy in Early ATNDialysis Clinic, Inc.Phase 2/Phase 3
Vasodilators and Anti-Oxidant Therapy in Early ATNSoutheast Renal Research InstitutePhase 2/Phase 3
Study of CYR-101 in Patients With SchizophreniaCyrenaic PharmaceuticalsPhase 2

See all CYR-101 clinical trials

Clinical Trial Summary for CYR-101

Top disease conditions for CYR-101
Top clinical trial sponsors for CYR-101

See all CYR-101 clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.